e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
Clinical aspects of asthma and allergic respiratory diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Mite-induced asthma treatment: Budesonide/formoterol vs. fluticasone/salmeterol
I. Sygaieva (Kiev, Ukraine)
Source:
Annual Congress 2010 - Clinical aspects of asthma and allergic respiratory diseases
Session:
Clinical aspects of asthma and allergic respiratory diseases
Session type:
Thematic Poster Session
Number:
1389
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Sygaieva (Kiev, Ukraine). Mite-induced asthma treatment: Budesonide/formoterol vs. fluticasone/salmeterol. Eur Respir J 2010; 36: Suppl. 54, 1389
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Mycosis induced asthma treatment: fluticasone/salmeterol vs. budesonide/formoterol reinforced by montelukast
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?
Source: Eur Respir J 2005; 26: 819-828
Year: 2005
Pharmacoeconomic analysis of beclomethasone/formoterol versus fluticasone/salmeterol in the treatment of moderate-severe asthma in Spain
Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment
Year: 2008
Economic evaluation of beclomethasone/formoterol versus budesonide/formoterol in the treatment of patient with moderate-severe asthma in Spain
Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment
Year: 2008
Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma
Source: Eur Respir J 2007; 29: 682-689
Year: 2007
Response to therapy with fluticasone propionate/salmeterol 250/50 or ipratropium/albuterol in population subgroups of patients with COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 336s
Year: 2005
Efficacy of salmeterol/fluticasone pMDI
versus
DPI in patients with asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 499s
Year: 2006
Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations
versus
a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006
Treatment effectiveness and exacerbations during one year with seretide compared to fluticasone propionate and salmeterol in mild-to-moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001
Single inhaler therapy (SiT) with budesonide/formoterol (BUD/FM) is effective in asthma control
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005
Fluticasone/salmeterol combination (FP/S) for immediate post-exacerbation treatment of childhood asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 159s
Year: 2005
Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 509s
Year: 2004
Plume characteristics of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
Seasonality of asthma exacerbations: efficacy of fluticasone furoate/vilanterol 100/25µg (FF/VI) vs fluticasone furoate 100µg (FF) alone
Source: International Congress 2017 – Asthma management
Year: 2017
Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012
Benefit of budesonide/formoterol compared with salmeterol/fluticasone in COPD patients in the morning
Source: Annual Congress 2009 - Healthcare and treatment of COPD
Year: 2009
Effects of budesonide/formoterol combination therapy versus budesonide on airway dimensions in asthma
Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Year: 2012
Fluticasone/formoterol combined in a single aerosol inhaler vs budesonide/formoterol for the treatment of asthma: A non-inferiority trial
Source: Annual Congress 2011 - Asthma: control and treatment
Year: 2011
Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD
Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD
Year: 2020
Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone
Source: Eur Respir J 2001; 18: 262-268
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept